Plegridy is approved for treating relapsing forms of multiple sclerosis (MS) in adults [1]. This indication includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [1].
What is Plegridy and how does it work?
Plegridy is a brand name for peginterferon beta-1a, an injectable medication used in the treatment of multiple sclerosis [1]. It is a longer-acting form of interferon beta-1a, which is a type of biological drug that mimics naturally occurring proteins in the body called interferons [2]. Interferons are believed to play a role in the immune system and inflammation. By administering Plegridy, the aim is to reduce the frequency of relapses and slow the progression of physical disability in MS patients [1].
How is Plegridy administered?
Plegridy is administered via subcutaneous injection, meaning it is injected just under the skin [1]. It is typically given every two weeks [1]. The availability of a pre-filled pen and pre-filled syringe can simplify administration for patients [2].
What is the difference between Plegridy and other MS treatments?
Plegridy belongs to the class of medications known as disease-modifying therapies (DMTs) for MS [1]. Other DMTs include injectables like Avonex (interferon beta-1a) and Copaxone (glatiramer acetate), as well as oral medications and infusions. Plegridy's advantage lies in its dosing frequency, requiring an injection every two weeks, which is less frequent than some other injectable interferons [2]. However, the choice of treatment depends on individual patient factors, disease severity, and physician recommendation.
What clinical data supports Plegridy's efficacy?
Clinical trials have demonstrated Plegridy's effectiveness in reducing relapse rates and slowing disability progression in individuals with relapsing forms of MS [1]. For example, the ADVANCE trial showed a significant reduction in annualized relapse rate compared to placebo [1].
When does Plegridy's patent expire?
Information regarding specific patent expiry dates for Plegridy is available on drug patent databases. For instance, DrugPatentWatch.com provides detailed patent information that can be accessed to determine exclusivity periods for Plegridy [3].
Who manufactures Plegridy?
Plegridy is manufactured by Biogen [1].
What are the potential side effects of Plegridy?
Common side effects associated with Plegridy include injection site reactions (redness, swelling, pain), flu-like symptoms (fever, headache, muscle aches, chills), fatigue, and nausea [1]. More serious side effects can occur, though they are less common. These can include depression, mood changes, liver problems, and changes in blood cell counts [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there alternatives to Plegridy for MS treatment?
Yes, there are numerous alternative treatments available for relapsing forms of MS. These include other injectable interferons, glatiramer acetate, various oral medications (such as fingolimod, teriflunomide, and dimethyl fumarate), and intravenous infusion therapies [4]. The selection of an alternative depends on factors such as efficacy, safety profile, tolerability, and route of administration.
What are the costs associated with Plegridy?
The cost of Plegridy, like other specialty medications, can vary significantly depending on insurance coverage, pharmacy, and geographic location. Information on pricing and potential patient assistance programs may be available through the manufacturer or specialized pharmaceutical pricing websites [3].
---
1. Plegridy Prescribing Information. https://www.plegridy.com/pdf/prescribing-information.pdf
2. Biogen. Plegridy (peginterferon beta-1a). https://www.biogen.com/en_us/products/neurology/plegridy.html
3. DrugPatentWatch. https://drugpatentwatch.com/
4. National Multiple Sclerosis Society. Treatments for Multiple Sclerosis. https://www.nationalmssociety.org/Living-with-MS/Treatments/Approved-Medications